论文部分内容阅读
目的观察慢性肝病患者血清胆碱酯酶治疗前后的变化以判断预后。方法选取420例确诊为慢性肝病患者的临床资料进行分析。结果慢性肝炎中度、重度、肝硬化患者血清胆碱酯酶水平变化依病情的轻重而表现出高低。肝硬化存活组57例,血清胆碱酯酶水平为(2 826.4±918.5)U/L;死亡组46例,血清胆碱酯酶水平为(1 312±427.2)U/L,两组比较差异有统计学意义(P<0.01)。结论患者的血清胆碱酯酶水平越低,其病情越严重,血清胆碱酯酶活性水平低者预后差,病死率高。血清胆碱酯酶能比较敏感而特异性反应出肝脏合成代谢功能,因此血清胆碱酯酶可作为病情预测及其预后的重要检测指标之一。
Objective To observe the changes of serum cholinesterase in patients with chronic liver disease before and after treatment to determine the prognosis. Methods The clinical data of 420 patients diagnosed as chronic liver disease were selected for analysis. Results of chronic hepatitis, moderate, severe, cirrhosis patients with changes in serum cholinesterase levels according to the severity of the disease showed high and low. 57 cases of liver cirrhosis survived, serum cholinesterase level was (2 826.4 ± 918.5) U / L; 46 cases died, serum cholinesterase level was (1312 ± 427.2) U / L, There was statistical significance (P <0.01). Conclusion The lower the level of serum cholinesterase in patients, the more severe the disease, the lower the level of serum cholinesterase activity is poor prognosis, high mortality. Serum cholinesterase can be more sensitive and specific response to the synthesis of liver metabolism, so serum cholinesterase can be used as an important prognostic indicator and prognostic indicators.